Browse the evidence

GLP-1 receptor agonists or co-agonists have demonstrated substantial and sustained weight loss along with notable improvements in cardiometabolic markers.

Practitioners may consider GLP-1 receptor agonists as effective options for weight management and improving cardiometabolic health.

Combination strategies using endoscopic bariatric therapies (EBTs) and anti-obesity medications (AOMs) result in greater total-body weight loss than either modality alone.

Combining EBTs with AOMs may enhance weight loss outcomes for patients.

Lifestyle modifications can mitigate cancer risk associated with obesity.

Encouraging lifestyle changes can be a key strategy in cancer prevention efforts.

Novel medications such as GLP-1 agonists have demonstrated sustained weight loss in patients with obesity.

Practitioners can consider GLP-1 agonists as a treatment option for obesity.

The FDA authorizes the use of injectable semaglutide for the treatment of obesity.

Practitioners can consider semaglutide as an approved treatment option for obesity in the U.S.

A comprehensive approach is the best way to manage weight.

Practitioners should consider a multifaceted approach to obesity treatment.

Use of GLP‐1 or GLP‐1/GIP RA therapy after lung transplantation was effective at decreasing weight and improving hemoglobin A1c.

Practitioners can consider GLP-1 and GLP-1/GIP RA therapies for weight management and glycemic control in lung transplant patients.

Adding semaglutide to usual care in US adults without diabetes is projected to avert 358,400 major adverse cardiovascular events (MACE) at a cost of $148,100 per quality-adjusted life-year (QALY) gained.

Semaglutide may be a beneficial addition to treatment plans for eligible patients to reduce cardiovascular risks.

Tirzepatide is effective in glucose control and weight reduction.

Tirzepatide can be considered a viable option for improving glycemic control and aiding weight loss in diabetic patients.

A prolonged lapse in GLP-1 receptor agonist therapy warrants consideration of reinitiation at a reduced dose.

Practitioners should consider starting patients on a reduced dose after a significant therapy lapse.

Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.

Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.

Tirzepatide is effective in reducing body weight and controlling blood glucose levels.

Tirzepatide can be considered a viable treatment option for patients struggling with weight and blood glucose management.

Carbohydrate-restricted diets (CRDs) significantly improved glycemic control, including glucose (SMD = -2.94 mg/dL), insulin (SMD = -8.19 pmol/L), and HOMA-IR (-0.54).

Practitioners may consider CRDs as an effective strategy for improving glycemic control in adults.

48.2% of patients who were ineligible for transplant due to elevated body mass index achieved waitlist activation after successful weight loss.

Successful weight loss with semaglutide can enhance transplant eligibility for patients.

Semaglutide initiated 6 months post LSG results in significantly greater absolute weight loss of 14.03 ± 5.26 kg compared to 5.63 ± 6.25 kg in controls from 6 to 12 months post LSG (p < 0.0001).

Practitioners may consider semaglutide as an effective adjunct therapy for weight management in patients post-sleeve gastrectomy.

Semaglutide therapy leads to a higher percentage weight loss of 12.61% ± 4.11% compared to 4.84% ± 5.18% in controls from 6 to 12 months post LSG (p < 0.0001).

Semaglutide may be recommended for patients post-surgery to enhance weight loss outcomes.

At 12 months, total weight loss was higher in the treatment group (35.77% ± 8.35%) compared to controls (28.37% ± 7.41%; p < 0.0001).

The findings support the use of semaglutide for improved long-term weight management post-surgery.

Patients with a longer duration of GLP-1RA treatment are more likely to achieve successful weight reduction at follow-up of 12 months (OR = 1.014).

Practitioners should consider the duration of GLP-1RA treatment as a factor in achieving weight loss.

Using semaglutide is associated with successful weight reduction at the follow-up of 6 months (OR = 2.138).

Semaglutide may be a more effective option for weight reduction in patients treated with GLP-1RA.

GLP-1 receptor agonists produced greater weight loss among women (10.9%; 95% CI, 7.0%-14.8%) than men (6.8%; 95% CI, 4.6%-9.0%).

Practitioners should consider gender differences when prescribing GLP-1 receptor agonists for weight loss.

GLP-1-based medications can achieve up to 24% weight loss, aiding in the effective management of obesity and its complications.

Practitioners can consider GLP-1 medications as a viable option for weight management in obese patients.

Semaglutide, a GLP-1 receptor agonist, can lead to weight reductions of up to 15%.

Practitioners should consider the potential effectiveness of semaglutide for weight loss in patients.

Incretin-based therapies induced substantial weight loss, mostly from fat mass.

Practitioners can consider incretin-based therapies as effective options for promoting fat loss in T2D patients.

Broad access to semaglutide would result in 38,950 cardiovascular events avoided and 6,180 deaths avoided over a 10-year period.

Practitioners should consider the significant health benefits of prescribing semaglutide to eligible Medicare patients.